Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an announcement.
Paradigm Biopharmaceuticals Limited has announced the quotation of 8,300,335 ordinary fully paid securities on the ASX, effective from September 9, 2025. This move is part of the company’s strategy to enhance its market presence and provide additional value to its stakeholders by expanding its capital base.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for various diseases. The company is primarily engaged in creating treatments that address unmet medical needs, leveraging its expertise in drug repurposing and development.
Average Trading Volume: 834,288
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$113M
See more data about PAR stock on TipRanks’ Stock Analysis page.